Quarterly report pursuant to Section 13 or 15(d)

Segment Information

v3.10.0.1
Segment Information
 9 Months Ended
Sep. 30, 2018
Segment Reporting [Abstract]  
Segment Information
20.
Segment Information
 
The Company operates in three
 operating and
reportable segments, Dermatology Product Sales, Pharmaceutical and Biotechnology Product Development and National. The accounting policies of the Company’s segments are the same as those described in Note 2. The following tables summarize, for the periods indicated, operating results by reportable segment:
  
Cost of goods sold is directly related to product sales only. Revenues derived from co-promote revenue had no cost of goods sold.
 
($ in thousands)
Three Months Ended September 30, 2018
 
Dermatology
Products
Sales
 
 
Pharmaceutical
and
Biotechnology
Product
Development
 
 
National
 
 
Consolidated
 
Net Revenue
 
$
5,168
 
 
$
5
 
 
$
58,520
 
 
$
63,693
 
Direct cost of goods
 
 
(1,406
)
 
 
–
 
 
 
-
 
 
 
(1,406
)
Sales and marketing costs
 
 
(2,754
)
 
 
–
 
 
 
–
 
 
 
(2,754
)
Research and development
 
 
–
 
 
 
(19,788
)
 
 
–
 
 
 
(19,788
)
General and administrative
 
 
(505
)
 
 
(8,925
)
 
 
–
 
 
 
(9,430
)
National expenses
 
 
–
 
 
 
–
 
 
 
(55,204
)
 
 
(55,204
)
Segment income (loss) from operations
 
$
503
 
 
$
(28,708
)
 
$
3,316
 
 
$
(24,889
)
Segment assets
 
$
10,765
 
 
$
157,781
 
 
$
56,373
 
 
$
224,919
 
 
 
 
Dermatology
 
 
Pharmaceutical
and
Biotechnology
 
 
 
 
 
 
 
($ in thousands)
 
Products
 
 
Product
 
 
 
 
 
 
 
Three Months Ended September 30, 2017
 
Sales
 
 
Development
 
 
National
 
 
Consolidated
 
Net Revenue
 
$
2,170
 
 
$
350
 
 
$
44,366
 
 
$
46,886
 
Direct cost of goods
 
 
(505
)
 
 
–
 
 
 
–
 
 
 
(505
)
Sales and marketing costs
 
 
(2,786
)
 
 
–
 
 
 
–
 
 
 
(2,786
)
Research and development
 
 
–
 
 
 
(16,190
)
 
 
–
 
 
 
(16,190
)
General and administrative
 
 
(349
)
 
 
(11,969
)
 
 
–
 
 
 
(12,318
)
National Expenses
 
 
–
 
 
 
–
 
 
 
(47,690
)
 
 
(47,690
)
Segment loss from operations
 
$
(1,470
)
 
$
(27,809
)
 
$
(3,324
)
 
$
(32,603
)
Segment assets
 
$
7,362
 
 
$
160,038
 
 
$
77,691
 
 
$
245,091
 
 
($ in thousands)
Nine Months Ended September 30, 2018
 
Dermatology
Products
Sales
 
 
Pharmaceutical
and
Biotechnology
Product
Development
 
 
National
 
 
Consolidated
 
Net Revenue
 
$
17,366
 
 
 
525
 
 
$
165,061
 
 
$
182,952
 
Direct cost of goods
 
 
(4,546
)
 
 
–
 
 
 
–
 
 
 
(4,546
)
Sales and marketing costs
 
 
(8,443
)
 
 
–
 
 
 
–
 
 
 
(8,443
)
Research and development
 
 
–
 
 
 
(62,332
)
 
 
–
 
 
 
(62,332
)
General and administrative
 
 
(1,270
)
 
 
(29,075
)
 
 
–
 
 
 
(30,345
)
National expenses
 
 
–
 
 
 
–
 
 
 
(162,258
)
 
 
(162,258
)
Segment income (loss) from operations
 
$
3,107
 
 
$
(90,882
)
 
$
2,803
 
 
$
(84,972
)
Segment assets
 
$
10,765
 
 
$
157,781
 
 
 $
56,373
 
 
$
224,919
 
 
 
 
Dermatology
 
 
Pharmaceutical
and
Biotechnology
 
 
 
 
 
 
 
($ in thousands)
 
Products
 
 
Product
 
 
 
 
 
 
 
Nine Months Ended September 30, 2017
 
Sales
 
 
Development
 
 
National
 
 
Consolidated
 
Net Revenue
 
$
8,309
 
 
$
1,393
 
 
$
132,563
 
 
$
142,265
 
Direct cost of goods
 
 
(1,852
)
 
 
–
 
 
 
–
 
 
 
(1,852
)
Sales and marketing costs
 
 
(7,663
)
 
 
–
 
 
 
–
 
 
 
(7,663
)
Research and development
 
 
–
 
 
 
(38,077
)
 
 
–
 
 
 
(38,077
)
General and administrative
 
 
(961
)
 
 
(27,866
)
 
 
–
 
 
 
(28,827
)
National Expenses
 
 
–
 
 
 
–
 
 
 
(139,219
)
 
 
(139,219
)
Segment loss from operations
 
$
(2,167
)
 
$
(64,550
)
 
$
(6,656
)
 
$
(73,373
)
Segment assets
 
$
7,362
 
 
$
160,038
 
 
$
77,691
 
 
$
245,091